PHASE-II EVALUATION OF AMSA IN PATIENTS WITH METASTATIC LUNG-CANCER

  • 1 January 1980
    • journal article
    • research article
    • Vol. 64  (12) , 1383-1385
Abstract
Patients (54) with metastatic lung cancer were treated with AMSA [4''-[(9-acridinyl)amino]methanesulfon-m-anisidide]. Patients with a performance score of 0-1, no prior chemotherapy and normal liver function received a dose of 35 mg/m2 per day i.v. for 3 days every 4 wk; patients with a performance score of 2-3, any prior chemotherapy or abnormal liver functions received a dose of 30 mg/m2 per day on the same schedule. Among 53 evaluable patients, responses were noted in 1 with adenocarcinoma and in 2 with squamous cell carcinoma (overall response rate, 6%). AMSA apparently has limited activity in lung cancer when used in this schedule except perhaps in previously untreated squamous cell carcinoma. Only a limited number of patients with large cell or small cell carcinoma were treated.

This publication has 0 references indexed in Scilit: